Onye ọrịa Australia nwetara nzaghachi dị ịrịba ama n'oge site na ọgwụgwọ DLBCL/CD20 nke BIOOCUS Medical Group maka DLBCL agbakeghachiri.

A chọpụtara na Rodney Charles Monger, nwoke dị afọ iri isii na asatọ si mba Australia nwere nnukwu ọrịa kansa. B-Cell Lymphoma (DLBCL) afọ atọ gara aga. Ọ chọrọ nlekọta dị elu, ọ gara na BIOOCUS Medical Group na Ọgọst 2025. Nnyocha biopsy nke node lymph node cervical gosipụtara na lymphoma B-cell nke sitere na etiti germinal. Immunohistochemistry nwere ezigbo mmetụta maka CD20, CD19, na CD10, yana oke ngosipụta nke Bcl-6, Bcl-2 (70%+), na c-MYC (60%+). Nnwale mkpụrụ ndụ ihe nketa gosipụtara nhazi BCL2 site na FISH na mgbanwe na mkpụrụ ndụ ihe nketa EZH2, KMT2D, TNFRSF14, NRAS, na TPMT - ihe nrịbama doro anya nke profaịlụ siri ike, nke nwere nnukwu ihe egwu.

Mgbe ha natara ọgwụ pola yana ọgwụ mgbochi BTK na lenalidomide, tinyere ọgwụ chemotherapy nke FC lymphodepletion, ọrịa Maazị Monger nọgidere na-adịghị ike. Ndị otu BIOOCUS Medical Group kwadoro ọgwụgwọ mkpụrụ ndụ CD19/CD20 CAR-T ọhụrụ ha nke nwere ike ibute nsogbu abụọ.

Na Septemba 8, 2025, Maazị Monger natara mkpụrụ ndụ CD19/CD20 CAR-T nke nwere onwe ya. Ihe dị ịtụnanya bụ na ọ nweghị ọrịa cytokine release syndrome (CRS) na enweghị ọrịa neurotoxicity metụtara sel immunoeffector (ICANS), nke butere usoro ọgwụgwọ dị mma mgbe a mịnyechara ya nke mere ka ọ kwụsie ike ma nwee olileanya site na ụbọchị mbụ.

Nleba anya ọbara dị n'akụkụ gosiri mmụba dị egwu nke mkpụrụ ndụ CAR-T, na-egosi na e tinyere ha n'ime akpa na mmụba dị mma. N'ụbọchị nke anọ mgbe e tinyere ha n'ime akpa, mkpụrụ ndụ CAR19+ bụ 0.50% nke mkpụrụ ndụ CD3+ T (uru zuru oke bụ 6.04 × 10⁷/L) na mkpụrụ ndụ CAR20+ 0.41% (4.96 × 10⁷/L). Ka ọ na-erule ụbọchị nke asaa, CAR19+ rịrị elu ruo 1.68% (1.40 × 10⁷/L) na CAR20+ ruo 1.63% (1.36 × 10⁷/L). N'ụbọchị nke iri, CAR19+ ruru 31.43% nke mkpụrụ ndụ CD3+ T (uru zuru oke bụ 3.13 × 10⁸/L) na CAR20+ ruru 32.74% (uru zuru oke bụ 3.26 × 10⁸/L). Sistemụ mmiri ahụ gosikwara nkesa ziri ezi n'ofe obere CD4+ na CD8+ nwere nnukwu ngosipụta CAR abụọ, na-egosi ikike ọgwụgwọ ahụ iji kwalite ntachi obi na mmụba siri ike n'ime ndụ.

N'oge nyocha kachasị ọhụrụ (ụbọchị nke iri), Maazị Monger na-aga n'ihu na-eme nke ọma n'ụlọọgwụ. Ọ na-aṅụ ọgwụ a na-eji ọnụ eme ihe nke gụnyere acyclovir, sulfamethoxazole compound, orelabrutinib, lenalidomide, na ihe ndị na-enyere aka, na-enyocha ọnụọgụ ọbara, ọrụ imeju na akụrụ, yana ihe nrịbama mbufụt mgbe niile.

Ndị otu BIOOCUS Medical Group nyere nkwado zuru oke, nke lekwasịrị anya na ndị ọrịa n'oge niile, gụnyere ebe obibi dị mma, nri na-edozi ahụ, enyemaka njem, na ndụmọdụ uche maka Maazị Monger na ezinụlọ ya. Ụzọ a zuru oke nyere ya ohere ilekwasị anya nke ọma na mgbake.

Ihe gbasara Maazị Monger na-egosi ike mgbanwe nke ọgwụgwọ BIOOCUS Medical Group CD19/CD20 CAR-T abụọ maka ndị ọrịa nwere DLBCL na-alaghachi azụ/na-anaghị emegharị ahụ. Mgbasawanye ngwa ngwa na nke siri ike nke mkpụrụ ndụ CAR-T na-enweghị nnukwu nsí na-egosipụta njirimara nchekwa dị mma nke ngwaahịa ahụ na ọrụ mgbochi etuto ahụ siri ike - ọbụlagodi na onye ọrịa meworo agadi nwere njirimara molekul dị elu.